Combination of early pushing with extended second stage increases the rates of spontaneous vaginal deliveries, but might be associated with adverse maternal and neonatal outcomes.

OBJECTIVE: To evaluate the effect of combining the technique of early pushing and extended second stage on the mode of delivery, as well as adverse maternal and neonatal outcomes. STUDY DESIGN: This retrospective data analysis included all women delivering in a single tertiary medical center through 2015-2020. In January 2017 the protocol of second-stage management was changed to a combination of extended second stage (i.e., addition of an extra-hour to the traditional Friedman cutoffs), as well as early pushing (i.e., initiation of active pushing within the first 30 min of full dilatation). We compared delivery outcomes in women reaching full dilatation during January 2015-December 2016, vs. January 2017-July 2020. RESULTS: Of the 15,792 parturients, 10,418 (66.0%) were managed using the "new" protocol. No difference was found in terms of baseline characteristics, except for higher rates of neuraxial analgesia (72.8% vs. 70.4%, p = 0.002) and induction of labor (22.4% vs. 17.8%, p < 0.0001) during the new protocol period. In subgroup analysis by parity and neuraxial analgesia, no change was noted in the rate of cesarean deliveries. A significant increase in spontaneous vaginal deliveries (SVD) in favor of the "new" protocol was noted, except for multiparous women with no analgesia. In addition, in primiparous women with neuraxial analgesia, a decrease in vacuum deliveries was noted. In secondary outcome analysis, a significant increase in postpartum hemorrhage and a decrease in umbilical base excess values was noted in women with neuraxial analgesia, both primi- and multiparous. DISCUSSION: Early pushing along with extension of the second stage was associated with higher rate of SVD, at the expense of increased risk for maternal postpartum hemorrhage. Thus, combination of these two techniques must be practiced with caution.

Changes in the obstetrical emergency department profile during the COVID-19 pandemic.

BACKGROUND: The COVID-19 outbreak caused persons to be reluctant to seek medical care due to fear of contracting the infection. OBJECTIVES: To evaluate the effect of the COVID-19 pandemic on admission rates to the delivery room and the feto-maternal unit, and to assess the effect on the nature of presenting obstetrical complaints to the emergency department. STUDY DESIGN: A retrospective cohort study in one medical center. The population was women > 20 weeks pregnant who presented to the obstetrical emergency department with self-complaints during 29 days at the peak of the pandemic outbreak, and a matched group during the exact period in the previous year. We compared between the groups: clinical, obstetrical, and demographic data, including age, area of residence, gravidity, parity, previous cesarean deliveries, high-risk pregnancy follow-up, the last 30 days admissions to the obstetrical emergency department, gestational age, chief complaints, cervical dilatation, cervical effacement, admissions to the delivery room or feto-maternal unit, time from admissions to the delivery room to birth, if applicable, and acute obstetrical complications diagnosed at the emergency department. RESULTS: During the pandemic outbreak, 398 women met study inclusion criteria, compared to 544 women in the matched period of the previous year. During the COVID-19 period, women visited the obstetrical emergency department at a more advanced mean gestational age (37.6 ± 3.7 vs. 36.7 ± 4.6, p = .001). Higher proportions of women in the COVID-19 cohort presented in active labor, defined by cervical dilation of at least 5 cm on admission to the labor ward [37 (9.3%) vs 28 (5.1%), p = .013)] and with premature rupture of membranes [82 (20.6%) vs 60 (11.0%), p < .001)], and consequently with more admissions to the delivery room [198 (49.7%) vs 189 (34.7%), p < .001)]. We also recorded a significant increase in urgent obstetrical events in the emergency department during the recorded COVID-19 pandemic [23 (5.8%) vs 12 (2.2%)), p = .004]. However, the rates of neonatal and maternal morbidity did not change. During the outbreak the proportion of visits during the night was higher than during the matched period of the previous year: [138 (34.7%) vs 145 (26.6%)), p = .008]. In a multivariate logistic regression, the higher rates of admission to the delivery room during active labor and of urgent events during the pandemic outbreak compared to the matched period in the previous year remained statistically significant. CONCLUSIONS: The pandemic outbreak of COVID-19 caused a behavioral change among women who presented to the obstetrical emergency department. This was characterized by delayed arrival to the obstetrical emergency department and the delivery room, which led to a significant increase in urgent and acute interventions. The change in behavior did not affect the rates of maternal and neonatal morbidity.

Maternal and Neonatal SARS-CoV-2 Immunoglobulin G Antibody Levels at Delivery After Receipt of the BNT162b2 Messenger RNA COVID-19 Vaccine During the Second Trimester of Pregnancy.

IMPORTANCE: BNT162b2 messenger RNA (mRNA) COVID-19 vaccination in the third trimester was found to be associated with a strong maternal humoral IgG response that crossed the placenta and approached maternal titers in the newborn. OBJECTIVE: To evaluate maternal and neonatal SARS-CoV-2 immunoglobulin G (IgG) antibody levels at birth after mRNA COVID-19 vaccination during the second trimester of pregnancy. DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study, conducted at a single medical center in Haifa, Israel, from May to July 2021, included women with a singleton pregnancy over 24 weeks of gestation at least 7 days after receipt of their second COVID-19 vaccine dose who were not known to be previously infected with COVID-19. EXPOSURES: BNT162b2 (Pfizer/BioNTech) vaccination. MAIN OUTCOMES AND MEASURES: The primary outcomes were SARS-CoV-2 IgG antibody titers measured in the parturient at admission and in the umbilical cord blood within 30 minutes after delivery. Secondary outcomes were the correlation between antibody titers, feto-maternal characteristics, maternal adverse effects after vaccination, and time interval from vaccination to delivery. RESULTS: Antibody levels were measured for 129 women (mean [SD] age, 31.9 [4.9] years) and 114 neonates, with 100% of the tests having positive results. The mean (SD) gestational age at administration of the second vaccine dose was 24.9 (3.3) weeks. Neonatal IgG titers were 2.6 times higher than maternal titers (median [range], 3315.7 [350.1-17 643.5] AU/mL vs 1185.2 [146.6-32 415.1] AU/mL). A positive correlation was demonstrated between maternal and neonatal antibodies (r = 0.92; 95% CI, 0.89-0.94). Multivariable analysis revealed that for each week that passed since receipt of the second vaccine dose, maternal and neonatal antibody levels changed by -10.9% (95% CI, -17.2% to -4.2%; P = .002) and -11.7% (95% CI, -19.0 to -3.8%; P = .005), respectively. For each 1-year increase in the mother's age, maternal and neonatal antibody levels changed by -3.1% (95% CI, -5.3% to -0.9%; P = .007) and -2.7% (95% CI, -5.2% to -0.1%; P = .04), respectively. CONCLUSIONS AND RELEVANCE: In this cohort study, receipt of the BNT162b2 mRNA COVID-19 vaccine during the second trimester of pregnancy was associated with maternal and neonatal humoral responses, as reflected in maternal and neonatal SARS-CoV-2 IgG antibody levels measured after delivery. These findings support COVID-19 vaccination of pregnant individuals during the second trimester to achieve maternal protection and newborn safety during the pandemic.

Group B Streptococcus real-time PCR may potentially reduce intrapartum maternal antibiotic treatment.

BACKGROUND: Protocols for preventing early-onset group B streptococcal (GBS) neonatal infection may result in unnecessary antibiotics administration. Real-time polymerase chain reaction (PCR) can provide a result within 30-60 min and has been found to be specific and sensitive for defining intrapartum GBS status. OBJECTIVE: To evaluate whether implementation of GBS fast real-time PCR to all women who require GBS prophylaxis may reduce the use of maternal prophylactic antibiotics. METHODS: This prospective cohort study included women admitted to a single delivery ward who required prophylactic antibiotics either due to a positive antepartum GBS culture screening performed at 35-37 weeks or due to an unknown GBS status with an intrapartum risk factor. All the women were tested by a double vaginal swab (real-time PCR and culture) as soon as it became apparent, they required antibiotic prophylaxis and prior to its administration. RESULTS: Between May 2019 and August 2020, 303 women met eligibility criteria and were enrolled, but four were excluded from the analysis due to failed culture or PCR tests. Of 299 women included in the study, 208 (69.5%) and 180 (60.2%) women, showed no evidence of GBS on intrapartum culture or PCR, respectively. Of 89 GBS antepartum carriers, 43 (48.3%) and 32 (35.9%) had negative intrapartum culture and PCR results, respectively. Of the 210 women with risk factors, 165 (78.5%) were culture negative and 148 (70.4%) had a negative PCR. Using intrapartum culture as the gold standard, intrapartum GBS real-time PCR was found to have a sensitivity of 97.8% (95% confidence interval [CI] 92.3, 99.7) and a specificity of 85.6% (95% CI 80.1, 90.1). CONCLUSIONS: Compared with antepartum universal culture screening or intrapartum risk-factor assessment, the need for maternal antibiotic treatment may be substantially reduced by implementation of intrapartum GBS real-time PCR, without compromising the sensitivity of GBS detection.

Guided training has a beneficial effect on umbilical cord blood sampling quality.

OBJECTIVE: Umbilical cord arterial blood gas analysis is important for neonatal assessment at birth, particularly for determining asphyxia. In April 2019, our labor ward faculty held systemic teaching sessions for midwives, aimed to describe and to exercise proper sampling from both the umbilical cord artery and vein, to ensure biological validity of the values obtained. Our aim was to estimate the rates of inadequate umbilical blood sampling and to evaluate the effect of guided training on the quality of sampling. STUDY DESIGN: This retrospective interventional cohort study included all the women admitted to the delivery room, with a record of postpartum umbilical cord blood sampling. Umbilical cord sampling was considered adequate if two measurements were recorded with a veno-arterial pH gradient of at least 0.02 and an arterio-venous pCO2 gradient of no less than 0.5 kPa. Rates of inadequate sampling were compared between women who gave birth in the year preceding and the year following the guidance. Clinical characteristics were compared between the groups of adequate and inadequate sampling. RESULTS: Overall, 3,779 women gave birth in the year preceding guidance, and 3,649 in the subsequent year. Of these, 1,112 (29.4%) and 1,105 (30.2%), respectively, underwent umbilical sampling. In the year following the guidance, 750 (67.8%) adequate samples were drawn compared to 692 (62.2%) prior the guidance. This difference demonstrated significant improvement (OR 1.28, 95% CI 1.07-1.52, P = 0.006) in umbilical vessel sampling. Following multivariate logistic regression, inadequate sampling was associated with newborn weight below 2500 g (aOR 1.6, 95% CI 1.2-2.1, p = 0.001), spontaneous vaginal delivery with a possible fetal metabolic abnormality (aOR 2.2, 95% CI 1.7-2.7, p < 0.001), and vacuum deliveries (aOR 1.9, 95% CI 1.5-2.5, p < 0.001). CONCLUSIONS: Guided training of proper umbilical blood sampling may reduce the rate of inadequate postpartum blood gas results. Labor wards should consider carrying out annual demonstrations of proper umbilical blood collection, with emphasis on factors that affect the quality of the samplings.

Consequences of the COVID-19 pandemic on the postpartum course: Lessons learnt from a large-scale comparative study in a teaching hospital.

OBJECTIVE: To evaluate the consequences of COVID-19 pandemic restrictions on the postpartum course. METHODS: A retrospective cross-sectional study compared women who gave birth between March and April 2020 (first wave), between July to September 2020 (second wave), and a matched historical cohort throughout 2017-2019 (groups A, B, and C, respectively). Primary outcomes were postpartum length of stay (LOS), presentations to the emergency department (ED), and readmissions 30 days or longer after discharge. Following Bonferroni correction, p < 0.016 was considered statistically significant. RESULTS: In total, 3377 women were included: 640, 914, and 1823 in groups A, B, and C, respectively. LOS after birth (both vaginal and cesarean) was shorter in groups A and B compared to the control group (2.28 ± 1.01 and 2.25 ± 0.93 vs 2.55 ± 1.10 days, p < 0.001). Rates of ED presentations 30 days after discharge were higher in groups C and B compared to group A (6.63% and 6.45% vs 3.12%, p = 0.006). Rates of readmissions 30 days after discharge were 0.78%, 1.42%, and 1.09% (groups A, B, and C, respectively), demonstrating no statistical difference (p = 0.408). CONCLUSION: During the COVID-19 pandemic, there was a reduction or no change in rates of ED presentations and readmissions, despite the shortened LOS after delivery. A shift in policy regarding the postpartum LOS could be considered.

Can recurrent cesarean section due to arrest of descent be predicted by newborn weight difference?

OBJECTIVE: To evaluate if newborn weight difference is associated with the mode of delivery in women with a previous cesarean section due to arrest of descent. STUDY DESIGN: This retrospective cohort analysis included all women admitted to the delivery room of Carmel Medical Center with a singleton fetus at vertex presentation and a prior cesarean section for arrest of descent. A comparison was made between women who had a subsequent successful vaginal birth after cesarean delivery vs. a repeat cesarean section for arrest of descent. The primary outcome was newborn weight difference between the previous cesarean section and the present delivery. Secondary outcomes were gestational age, gravidity, age, induction of labor, previous vaginal birth and epidural analgesia. RESULTS: Of 179 women with a prior cesarean section due to arrest of descent, 55 women (30.7 %) underwent an elective repeat cesarean section. Of the remaining 124 women, 95 women (76.6 %) achieved a vaginal delivery. Out of the 29 cases who underwent a repeat cesarean section, 18 women had a cesarean section for arrest of descent. Women who achieved vaginal delivery were more likely to be with higher gravidity, a previous vaginal delivery and a lower rate of epidural anesthesia. Following multivariate logistic regression, the women who required a cesarean section due to arrest of descent, had significantly higher birth weight in the current than in the previous pregnancy, compared to women achieving vaginal delivery (Odds Ratio 4.7, CI 95 % 1.4-15.7, P = 0.012). CONCLUSION: Current birth weight higher than the previous newborn weight in a cesarean section for arrest of descent is associated with lower likelihood of successful vaginal birth after cesarean delivery and therefore should be taken in consideration during fetal weight estimation and the decision on the mode of delivery. This issue should be explored in future prospective large-cohort studies.

The mutual effect of pregestational body mass index, maternal hyperglycemia and gestational weight gain on adverse pregnancy outcomes.

OBJECTIVE: To investigate the mutual effect of obesity, gestational diabetes (GDM) and gestational weight gain (GWG) on adverse pregnancy outcomes. METHODS: Charts of patients who delivered in our hospital between June 2001 and June 2006 singleton, live births >24 weeks gestation were reviewed. Univariate and multivariate logistic regression were used to assess pregnancy outcomes defined as large for gestational age (LGA), primary cesarean section (PCS) and a composite outcome of LGA and/or PCS. RESULTS: A total of 8595 women were included. Frequency of composite outcome increased with increasing body mass index (BMI), increasing hyperglycemia and above-recommended GWG. In the multivariate logistic regression analysis compared to women with normal BMI, odds ratio (OR) for composite outcome was 1.23 (95% confidence interval [CI] 1.06-1.44) in overweight women, OR = 1.86 (1.51-2.31) in obese women and in severe obesity OR = 2.97 (2.15-4.11). Compared to normoglycemic women, odds for composite outcome in women with abnormal glucose challenge test OR = 1.46 (1.20-1.79), impaired glucose tolerance OR = 1.65 (1.14-2.4) and GDM OR = 1.56 (1.16-2.10). Women with GWG above recommended had OR = 1.58, (1.37-1.81) for composite outcome. CONCLUSIONS: Higher pregestational BMI, maternal hyperglycemia and above-recommended GWG independently contribute to adverse pregnancy outcomes. Furthermore, there is mutual effect between these three factors and adverse outcomes. Appropriate pregestational weight and adequate GWG might reduce risk of adverse pregnancy outcomes.

Normal fasting plasma glucose levels during pregnancy: a hospital-based study.

OBJECTIVE: Recently, the International Association of Diabetes and Pregnancy Study Groups have suggested new criteria for the diagnosis of gestational diabetes including a fasting glucose level of ≥92 mg/dL. We determined reference levels for normal fasting plasma glucose levels throughout pregnancy and evaluated the new normal cut-off for fasting glucose level. METHODS: Charts of patients who delivered in our hospital between June 2001 and June 2006 were reviewed. Women with pregestational diabetes, fasting glucose level >105 mg/dL or delivery at <24 weeks were excluded. Fasting glucose levels were assessed in 11 time categories between three months prior and four months postpartum in 7946 women. RESULTS: Compared to preconception levels, fasting glucose levels decreased by a median of 3 mg/dL in the first trimester (81-78 mg/dL). During the third trimester a slight further glucose reduction was observed (median 76 mg/dL). After delivery fasting glucose levels increased sharply (84 mg/dL in the puerperium and 81 mg/dL by three months postpartum). Throughout pregnancy 5.2-9.0% of pregnant women had a fasting glucose level of ≥92 mg/dL [compared to 8.2% in the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study]. CONCLUSION: Fasting glucose levels decrease early in pregnancy with only slight further decrease later on. It seems that the same fasting glucose cut-off can be used throughout pregnancy for the diagnosis of gestational diabetes mellitus.

Pregestational body mass index, weight gain during pregnancy and maternal hyperglycemia.

OBJECTIVE: To evaluate the associations between pregestational BMI and weight gain during pregnancy and the risk for maternal hyperglycemia. METHODS: The charts of all patients who delivered at our hospital between June 2001 and June 2006 were reviewed. Maternal hyperglycemia categories were defined as GDM (by the Carpenter and Coustan criteria); Impaired glucose tolerance (IGT - only one abnormal value in the 100 g OGTT); Abnormal GCT (≥140 mg/dL) but no high values on the OGTT. Women with GCT < 140 were defined as normal glucose tolerance (NGT). RESULTS: Pregravid BMI and glucose tolerance data were available for 9269 women. We also had data on weight gain during pregnancy for 7766 of these women. There was strong graded association between increasing BMI category and all levels of maternal hyperglycemia. There was significant negative correlation between BMI and weight gain during pregnancy (R = -0.251, P value < 0.0001). However, in the multivariate logistic regression model, only pregestational BMI was significantly associated with maternal hyperglycemia, whereas weight gain during pregnancy was no longer significant. CONCLUSIONS: Obesity is a strong predictor for gestational maternal hyperglycemia. Weight gain during pregnancy has less effect. Every effort should be made for pregestational weight reduction in overweight women.

First trimester fasting hyperglycemia as a predictor for the development of gestational diabetes mellitus.

OBJECTIVE: Screening for gestational diabetes mellitus (GDM) is usually done at 24-28 weeks of gestation. Our goal was to study the association between first trimester fasting plasma glucose level and GDM risk and to evaluate its efficacy as a screening test for GDM in comparison to a traditional risk factor, pregestational body mass index (BMI). STUDY DESIGN: The charts of all patients who delivered in our hospital between June 2001 and June 2006 were reviewed. Only subjects with a singleton pregnancy and a recorded first trimester fasting glucose level and BMI were studied. Women with pregestational diabetes mellitus, fasting glucose level >105mg/dl or delivery at <24 weeks were excluded. Screening properties of both fasting glucose level and BMI were calculated and compared using receiver operator characteristic curves. RESULTS: GDM was diagnosed in 135 of the 4876 women included in this study. Fasting glucose cut-off levels of 80-85mg/dl yielded sensitivities of 75-55% and specificities of 52-75% for GDM prediction. BMI cut-off values of 25-28 had sensitivities of 60-40% and specificities of 72-86% for GDM prediction. Receiver operator curves for fasting glucose levels and BMI showed similar performance in predicting GDM (area under curve 0.72±0.023 vs. 0.74±0.021 (P=0.44)). There was approximately a 1.5-fold increase in the risk of developing GDM with each 5mg/dl increase in fasting glucose or 3.5kg/m² increase in BMI. CONCLUSION: Higher first trimester fasting glucose levels, within the normoglycemic range, constitute an independent risk factor for the development of GDM among young pregnant women.

[Preconception care and counseling for women with diabetes and those at risk for diabetes].

Diabetes is a chronic disease with increasing incidence in recent years in parallel with the obesity epidemic. Diabetes can cause damage to many target organs and pregnancy in women with pregestational diabetes is considered a high risk pregnancy and constitutes a special challenge. Pregestational diabetes increases the risk of pregnancy complications to the mother, fetus and newborn infant. The duration and type of diabetes, its severity, the occurrence of chronic complications and the level of glucose control are the major factors influencing pregnancy outcome. Diabetes substantially increases the risk of spontaneous abortion and congenital malformations. In order to minimize these risks, it is important that all women with pregestational diabetes will receive appropriate preconception counseling and treatment.

First-trimester fasting hyperglycemia and adverse pregnancy outcomes.

OBJECTIVE: The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study found strong associations between higher levels of maternal glucose at 24-32 weeks, within what is currently considered normoglycemia and adverse pregnancy outcomes. Our aim was to evaluate the associations between first-trimester fasting plasma glucose level and adverse pregnancy outcomes. RESEARCH DESIGN AND METHODS: Charts of all patients who delivered at our hospital between June 2001 and June 2006 were reviewed. Only subjects with singleton pregnancy and a recorded first-trimester fasting glucose level were included. Women with pregestational diabetes, fasting glucose level >105 mg/dl, or delivery <24 weeks were excluded. Fasting glucose levels were analyzed in seven categories, similar to the HAPO study. The main outcomes were development of gestational diabetes mellitus (GDM), large-for-gestational-age (LGA) neonates and/or macrosomia, and primary cesarean section. Multivariate logistic regression analysis was used; significance was <0.05. RESULTS: A total of 6,129 women had a fasting glucose test at median of 9.5 weeks. There were strong, graded associations between fasting glucose level and primary outcomes. The frequency of GDM development increased from 1.0% in the lowest glucose category to 11.7% in the highest (adjusted odds ratio 11.92 [95% CI 5.39-26.37]). The frequency of LGA neonates and/or macrosomia increased from 7.9 to 19.4% (2.82 [1.67-4.76]). Primary cesarean section rate increased from 12.7 to 20.0% (1.94 [1.11-3.41]). CONCLUSIONS: Higher first-trimester fasting glucose levels, within what is currently considered a nondiabetic range, increase the risk of adverse pregnancy outcomes. Early detection and treatment of women at high risk for these complications might improve pregnancy outcome.

Evaluation of endothelial function in women with polycystic ovary syndrome.

OBJECTIVES: Previous studies have suggested that vascular reactivity may be altered in women with polycystic ovary syndrome (PCOS). We sought to evaluate the vascular reactivity specifically the endothelial function (EF) in women with PCOS and to study the effect of metformin on their EF. STUDY DESIGN: Thirty-one women diagnosed with PCOS and 33 healthy controls underwent evaluation of EF using a post-ischemia reactive hyperemia technique (Endo-PAT). EF was quantitatively determined as the ratio between the arterial pulse wave amplitude following a 5min arterial occlusion in the forearm to the pre-occlusion value. Oral metformin 850mg bid was administered to PCOS patients. After 3 months of treatment EF was reassessed using the same technique. RESULTS: The average endothelial function was 1.48+/-0.32 in the PCOS group versus 2.00+/-0.51 in the controls (P<0.001). There were no significant changes in the EF among the 18 patients who were treated with metformin, EF index pre- and post-treatment was 1.42 versus 1.43, respectively. CONCLUSIONS: Endothelial dysfunction is more likely to occur among PCOS patients than in healthy controls. These preliminary results suggest that metformin treatment for 3 months in PCOS patients does not improve endothelial function.